Arterial Ablation for the Treatment of Type 2 Diabetes Mellitus and Its Comorbidities

NCT ID: NCT05363761

Last Updated: 2023-03-21

Basic Information

• Recruitment Status: RECRUITING
• Clinical Phase: PHASE1
• Total Enrollment: 50 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2022-04-19
• Study Completion Date: 2029-01-31

Brief Summary

This study is assess the safety and performance of the Neurotronic Infusion catheter for treatment of patients with Type 2 Diabetes (T2DM) and hypertension.

Detailed Description

This study is a prospective, single-arm, multi-center trial to evaluate the safety and performance of use of the Neurotronic Infusion Catheter for chemical denervation of renal and hepatic arteries for treatment of patients with type 2 diabetes, hypertension, and obesity.

Conditions

Diabetes Mellitus, Type 2; Hypertension

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Ablation Treatment

Neurotronic Infusion Catheter Treatment

Group Type: EXPERIMENTAL

Neurotronic Infusion Catheter

Intervention Type: COMBINATION_PRODUCT

Denervation of renal and common hepatic arteries by ethanol ablation with the Neurotronic Infusion Catheter

Interventions

Neurotronic Infusion Catheter

Denervation of renal and common hepatic arteries by ethanol ablation with the Neurotronic Infusion Catheter

Intervention Type: COMBINATION_PRODUCT

Eligibility Criteria

Inclusion Criteria

Subjects must meet all of the following criteria to be eligible for participation in the study:

1. Age ≥ 21 and ≤ 65 years at time of enrollment.

2. Disease diagnosed

2.1 Diagnosed with T2DM with baseline:

1. Fasting plasma glucose ≥ 140 mg/dl (7.8 mmol/l) and ≤ 270 mg/dL (15 mmol/L)

2. HbA1c levels ≥ 7.0% and ≤ 9.0% (53-75 mmol/mol)

3. Triglyceride level < 400 mg/dL (4.52 mmol/L)

4. On oral anti-hyperglycemic drug regimen of metformin. Subjects may be on additional oral anti-hyperglycemic drug of a different drug class

5. Years of T2DM ≤ 10 years

And / Or

2.2 Diagnosed hypertension with baseline:

1. Office blood pressure of SBP of ≥ 140 mmHg and ≤ 180 mmHg and DBP ≥ 90 mmHg

2. Mean 24-hour ambulatory SBP of ≥ 130 mmHg and ≤ 170 mmHg with ≥ 75% valid readings

3. On stable oral anti-hypertension drug regimen consisting of up to a maximum of three drugs

3. BMI between 27.5 and 40 kg/m2

4. C-peptide testing: non-fasting random or stimulated C-peptide ≥ 2 ng/mL (660 pmol/L)

5. Vessel diameter of 3 mm to 7 mm with a minimum arterial treatable length of 20 mm in one or more of the following arteries:

• Renal
• Hepatic

Exclusion Criteria

1. T1DM or poorly controlled T2DM (defined as HbA1c > 9.0% or use insulin as medication to control glucose level).

2. Office diastolic blood pressure < 90 mmHg.

3. Current use of > 3 hypertension medications.

4. Currently on beta blockers.

5. One or more documented hyperglycemia episodes requiring hospitalization in the 180-day prior to screening date.

6. Prior evidence of hypoglycemia unawareness or serious hypoglycemia with loss of consciousness or confusion sufficient to prevent self-treatment in last 6 months.

7. BMI > 40 kg/m2.

8. Diagnosed proliferative retinopathy or evidence of peripheral neuropathy.

9. Lack of appropriate treatment site or anatomy precluding the intervention of the target arteries (renal and hepatic artery).

10. History of prior renal or hepatic artery intervention including balloon angioplasty, stenting, etc.

11. Arterial stenosis >50% of the normal diameter segment (diameter stenosis, compared to the angiographically normal proximal or distal segment).

12. Any abnormality or disease in one or more of the target arteries that, per the physician assessment, precludes the safe insertion of the guiding catheter (including, but not limited to, artery aneurysm, excessive tortuosity, calcification).

13. Occlusive peripheral vascular disease that would preclude percutaneous femoral access for the procedure.

14. Known or suspected secondary hypertension, such as Cushing's disease or Cushing's Syndrome, hyperaldosteronism, pheochromocytoma, thyroid and parathyroid abnormalities, history of pre-eclampsia, onset of hypertension prior to the age of 18.

15. Use of nonsteroidal anti-inflammatory drugs (NSAIDs) for two or more days per week over the month prior to enrollment.

16. Severe or unstable cardiovascular comorbidities, such as AMI or ACS, cardiac valve stenosis, pulmonary embolism, heart failure with NYHA Class III or IV, chronic atrial fibrillation, primary pulmonary hypertension, COPD.

17. Renal transplant, history of nephrectomy or single kidney, renal tumor/cancer, known non-functioning kidney, unequal renal size (>2 cm difference in renal length between kidneys associated with a chronic kidney disease or a deterioration of the kidney function), chronic renal deficiency with eGFR ≤ 60ml/min/1.73m2, or on chronic renal replacement therapy.

18. Prior liver transplant.

19. Any organ transplantation procedures are planned in the 365 days following Index Procedure.

20. Gastrointestinal permanent anatomic alteration surgery.

21. Any surgical procedure within 30 days prior to Index Procedure.

22. Currently taking the following medications within 90 days prior to screening and/or there is a need or anticipated need for these medications during the study:

1. Systemic Corticosteroids

2. Anticonvulsants

3. Centrally acting sympatholytics

23. Bleeding disorders, such as bleeding diathesis, thrombocytopenia, and severe anemia.

24. Use of anticoagulation therapy which cannot be discontinued from 7 days before or 14 days after the Index Procedure.

25. Any other condition(s) that would compromise the safety of the Subject or compromise study quality as judged by the investigator.

26. Significant alcohol consumption, defined as more than 2 drink units per day (equivalent to 20 g) in women and 3 drink units per day (equivalent to 30 g) in men, or inability to reliably quantify alcohol intake.

27. Active substance abuse, based on Investigator judgement, including inhaled or injected drugs, within 1 year prior to the initial screening.

28. Significant weight loss within the last 6 months (e.g., > 10% total body weight loss).

29. Hepatic decompensation defined as the presence of any of the following:

1. Serum albumin less than 3.5 g/dL

2. International normalization ratio (INR) greater than 1.4 (unless due to therapeutic anticoagulants)

3. Total bilirubin greater than 2 mg/dL with the exception of Gilbert syndrome

4. History of esophageal varices, ascites, or hepatic encephalopathy

30. ALT or AST greater than 200 U/L.

31. Diagnosis of liver cirrhosis.

32. Chronic liver or biliary disease of the following etiology:

1. History or diagnosis of Hepatitis B

2. History or diagnosis of Hepatitis C

3. History or diagnosis of current active autoimmune hepatitis

4. History or diagnosis of primary biliary cholangitis

5. History or diagnosis of primary sclerosing cholangitis

6. History or diagnosis of Wilson's disease

7. History or diagnosis of alpha-1-antitrypsin deficiency

8. History or diagnosis of hemochromatosis

9. History or diagnosis of drug-induced liver disease, as defined on the basis of typical exposure and history.

10. Known bile duct obstruction.

11. Suspected or proven liver cancer

33. History of acute or chronic pancreatitis.

34. Human immunodeficiency virus (HIV).

35. Subjects with a history of adverse reaction to heparin or heparin induced thrombocytopenia (HIT).

36. Systemic infection that the investigator judges would pose unacceptable procedural risks to the subject.

37. Known hypersensitivity to contrast media, nickel and ethanol that cannot be adequately pre-medicated.

38. Subject is depressed or on antidepressants.

39. Pregnancy or breastfeeding or plan to get pregnant in next 12 months.

40. Life expectancy of less than 5 years.

41. Unwilling or unable to comply with the follow-up study requirements.

42. Subjects or their legally authorized representatives unable to provide informed consent.

43. Concurrent medical condition that would affect the investigator's ability to evaluate the patient's condition or could compromise patient safety.

44. Currently participation in another pre-market drug or medical device clinical study.

• Minimum Eligible Age: 21 Years
• Maximum Eligible Age: 65 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Libra Medical

OTHER

Sponsor Role: collaborator

Neurotronic, Inc.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

John Chen, PhD

Role: STUDY_DIRECTOR

Neurotronic, Inc.

Locations

Hospital Paitilla Clinicas y Hospitales

Panama City, , Panama

Site Status: RECRUITING

Hospital Punta Pacifica

Panama City, , Panama

Site Status: RECRUITING

Sanatorio Adventista de Asunción

Asunción, , Paraguay

Site Status: RECRUITING

Countries

Panama; Paraguay

Central Contacts

Yunlong Zhang, MD

Role: CONTACT

pzhang@libramed.com

+1 669-203-9308

John Chen, PhD

Role: CONTACT

chenj@neurotronic.com

+1 763-273-6100

Facility Contacts

Guadalupe Perez, MD

Role: primary

Guadalupe Pérez

Role: primary

Rubén G Servían Campos, MD

Role: primary

Oscar L Paredes Gonzalez, MD, PhD

Role: backup

Other Identifiers

PR 2012

Identifier Type: -

Identifier Source: org_study_id